Home / Health / Guinea-Bissau Vaccine Study Sparks Global Ethics Debate
Guinea-Bissau Vaccine Study Sparks Global Ethics Debate
17 Jan
Summary
- US-funded study on hepatitis B vaccine timing raises ethical concerns.
- Critics fear erosion of trust in immunization in Guinea-Bissau.
- Study's fate is uncertain amid conflicting reports of cancellation.
A U.S.-funded study in Guinea-Bissau, investigating the health effects of hepatitis B vaccine dose timing on infants, has triggered significant ethical concerns. The $1.6 million grant awarded to Danish researchers by the U.S. Centers for Disease Control and Prevention is under scrutiny for its non-competitive nature.
Critics contend that randomizing infants to an "inferior" treatment, even if aligning with local norms, violates ethical research standards and risks undermining public trust in vaccines. This controversy occurs as the U.S. revises its own childhood immunization schedules, adding complexity to the debate.
The study's status is unclear, with the Africa CDC citing its cancellation due to an undated government document, while the U.S. Department of Health and Human Services maintains it will proceed. Past research by the Bandim Health Project has also faced criticism for methodological flaws.
